My only response would be that GTCB is following a well worn path for start-up pharmas and biotech companies. There's no science or skullduggery implied by this remark: It's simply an observed fact. Only really good, really big news is sufficient to stop the unending downward sawtooth curve that the share price of most of these companies seems to follow. You said you are getting nervous. I can't remember a time in the last ten years when I wasn't nervous about almost every biotech stock I held (and often with good reason). The only reason for increasing nervousness that I see is the fact that the F. D. A. has once again entered one of its drug prevention phases--and we've been there before, too. A lack of nervousness in biotech is the best way to get handed your head on a platter, no matter how soothing the alternative may seem. The only antidote I've found is to favor companies where the next binary event is in the near future. That way, the nervousness can be quickly replaced by elation or sheer terror!
Market Data 
Markets 
AI
